SUPPLEMENTAL MATERIAL

Title: A PSGL-1 Glycomimetic Reduces Thrombus Burden Without Affecting Hemostasis

Authors: Daniel J. Wong, Diane D. Park, Simon Park, Carolyn A. Haller, Jiaxuan Chen, Erbin Dai, Liying Liu, Appi Mandhapati, Pradheep Eradi, Bibek Dhakal, Walter Wever, Melinda Hanes, Lijun Sun, Richard D. Cummings, Elliot L. Chaikof



Supplemental Figure 1. MALDI profile of P-G6. Reflector positive ion mode with Super DHB matrix.



Supplemental Figure 2. Reverse phase HPLC profile of P-G6.



Supplemental Figure 3. **Validation of quantifying peptide.** Extracted ion chromatograms of the quantifying peptide from plasma of mice that were administered IV injections of (**A**) P-G6, (**B**) Saline, or (**C**) no injection. The spectrum list at retention time 18.68 min from mass range 1200-1204 *m*/*z* are listed below the chromatograms. The quantifying peptide was only observed in mice dosed with P-G6. Chromatograms displayed in **B-C** are plotted at an increased signal magnitude.





Anticoagulated mouse or human blood was dosed with saline, P-G6 (120 μ M), or anti-P-selectin (5 μ g/ml human KPL1, 5 μ g/ml mouse RB40.34) and platelets were activated with PAR peptide to examine platelet-leukocyte aggregation. (**Top row**) resting platelets displayed for reference; (**second row**) saline-treated, PAR activated; (**third row**) P-G6-treated, PAR activated; (**fourth row**) anti-P-selectin-treated, PAR activated. Samples were stained with species specific CD45 and anti-CD41-PE (mouse platelets) or anti-CD42a-PE (human platelets), monocytes and neutrophils were discerned by characteristic forward/side scatter. Representative scatter plots shown, gated box indicates % platelet-leukocyte aggregates (PLA+%).